top of page

Myopia Control Center

Myopia, or nearsightedness, is a common eye condition that is becoming more prevalent and increasing at an alarming rate in the United States in school-aged children especially with excessive nearwork in an ever more challenging academic environment as well as widespread usage of electronic devices such as computer, tablets, and smartphones. 

Besides experiencing the immediate negative effects of myopia now, children with high or progressive myopia may have other health ramifications later in life, including but not limited to retinal detachments, myopic maculopathy, glaucoma, and cataracts.  

It's 2024 and we have several options in our toolbox for myopia management and control to slow down progression based on multiple, established, and peer reviewed published studies. Please review them below!

Low Dose Atropine

Specifically formulated atropine eye drops dosed once daily.  

Low-dose atropine has emerged as a promising treatment option for myopia management, particularly in children and adolescents. Low-dose atropine is a type of medication that is used to relax the muscles in the eye, which can help slow down the progression of myopia.


Orthokeratology, also known as ortho-k, is a non-surgical treatment option that has been shown to slow down the progression of myopia. This treatment involves the use of specially designed gas-permeable contact lenses that are worn overnight while sleeping. These lenses gently reshape the cornea, which is the front surface of the eye, to correct the refractive error and reduce the progression of myopia. The lenses are removed in the morning, and the patient can enjoy clear vision throughout the day without the need for glasses or contact lenses. Studies have shown that ortho-k can effectively slow down the progression of myopia by up to 50%, making it an effective treatment option for children and adolescents with progressive myopia. Furthermore, ortho-k has also been found to be safe and well-tolerated by patients, making it a popular option for those seeking a non-surgical approach to myopia management.


First FDA approved daily disposable soft lenses for myopia control.

MiSight soft contact lenses are specifically designed to slow down the progression of myopia in children aged 8 to 12 years old. MiSight contact lenses work by providing a myopic defocus, which means that they create a slightly blurred image on the retina, stimulating the eye to slow down its growth and thus controlling the progression of myopia. These lenses are comfortable and easy to use, making them an attractive option for parents and children alike. Clinical studies have shown that wearing MiSight contact lenses can effectively reduce the progression of myopia by up to 59%, making them a promising treatment option for myopia control in children.

EyeZen Anti-Fatigue Lenses

In today's digital age, many people spend a significant amount of time looking at screens, such as computers, smartphones, and tablets, which can lead to eye strain and fatigue. To address this problem, eyewear manufacturers have developed a new type of lens called EyeZen or anti-fatigue lenses. These lenses are designed to help reduce the strain on the eyes caused by digital screens and other near-vision tasks. They work by incorporating a small amount of magnification at the bottom of the lens, which helps the eyes focus more easily on nearby objects, while also filtering out harmful blue light emitted by screens. 

Myopia Management Program Details

All myopia control or management programs are considered elective and not covered by vision or medical plan carriers. Fee schedule does not include the required annual routine exams often covered by vision or medical plan carriers.
Annual Program. Your commitment to scheduled follow-up appointments and adherence to treatment recommendations are essential for maximizing success.
Quarterly Assessment: Each custom tailored treatment approach includes quarterly measurement of the axial length of the eye to assess for myopia progression via specialized equipment otherwise routinely used for calculation of intraocular implants inserted during cataract surgery. Treatment may be adjusted during the year as necessary.
*Renewal/Reduced pricing is available for all plans when renewing the annual program within 30 days of expiration/anniversary and providing chart notes dated within 30 days of the annual comprehensive ocular exam from the referring doctor.


Initial year: $1900
Renewal*: $1400
Includes annual supply of MiSight contact lenses
bottom of page